# KLOW peptide: four peptides, one repair flower — what the studies show > KLOW peptide is a research-only four-peptide blend (KPV + GHK-Cu + BPC-157 + TB-500). A plain-English digest of what each component's literature measured — every figure cited. Four peptides, one vial — KPV, GHK-Cu, BPC-157 and TB-500. We surface what each component's published research actually measured, and where the blend itself has never been tested. ## The gist, in one bloom Here is the short, no-jargon version. KLOW peptide is not one molecule — it is a blend (a co-formulation: four separate peptides dissolved together in one vial). The four are KPV, GHK-Cu, BPC-157 and TB-500, and people lump them together because each one nudges a different step of how the body repairs tissue. Think of it as a flower with four petals: KPV calms inflammation, GHK-Cu (a tiny copper-carrying peptide) helps rebuild the skin's scaffolding, BPC-157 helps grow new blood vessels, and TB-500 helps cells crawl in to close a wound. Here is the honest part. Every one of those effects was measured for a single peptide on its own, mostly in cells and rats. Nobody has ever run a controlled study on the four-peptide KLOW blend itself. So the upside is real research — but it belongs to the parts, not the proven whole. What people report, including the downsides, is on [the effects page](/effects). ## What is KLOW peptide? KLOW peptide is a research-only co-formulation of four chemically distinct peptides — KPV, GHK-Cu, BPC-157 and TB-500 — supplied lyophilized (freeze-dried) in a single vial, most often at a total of 80 mg [4][6]. The four are co-dissolved at fixed mass ratios; they stay separate molecules and do not fuse into one new compound. There is no FDA-approved or pharmacopeial KLOW product. It is supplied strictly as a research-chemical mixture for laboratory use. Why four? Each petal occupies a different node of one tissue-repair signaling network. KPV suppresses inflammatory transcription [3]. GHK-Cu — the copper tripeptide (Gly-His-Lys carrying a copper ion) — drives matrix synthesis and shifts gene expression toward repair [4][5]. BPC-157, a 15-amino-acid peptide from gastric juice, promotes new blood-vessel growth [2]. TB-500, a short fragment of the larger protein thymosin beta-4, helps cells migrate [1]. The combination rationale is that these arms are complementary. The combination evidence does not exist yet — see [what is in the 80 mg KLOW vial](/composition). ## What does the KLOW peptide do? Mechanistically, the four arms target non-overlapping nodes of the same repair cascade. KPV suppresses NF-kappaB (the master switch a cell flips to turn on inflammation) and lowers pro-inflammatory cytokine output in epithelial and immune cells [3]. GHK-Cu acts at the transcriptome level — it shifts expression of a large fraction of assayed genes toward extracellular-matrix synthesis, antioxidant defense and DNA repair [5], and supplies copper for the enzymes that crosslink collagen [4][6]. BPC-157 phosphorylates VEGFR2 (the receptor that triggers new vessel growth) through the VEGFR2-Akt-eNOS pathway [12]. TB-500's LKKTET motif sequesters G-actin (it grabs the loose protein building blocks cells use to crawl), a step tied to cell migration and re-epithelialization [1]. What KLOW does *as a blend in humans* is untested. Every line above is a single-component finding. The four-petal picture is a map of separate studies, not a measured result for the mixture. ## What is KLOW peptide used for? In research framing, KLOW peptide is positioned around four nodes of one cascade: inflammation, matrix remodeling, angiogenesis (new blood-vessel growth), and wound closure — each traced to a specific component's literature. There is no validated human use for the blend itself. The single-component record is where the substance lives. GHK-Cu has decades of topical cosmetic and wound-healing human data [7] and a controlled hair-count trial of a GHK-containing topical [9]. BPC-157 has an extensive rodent tissue-repair literature [2] plus a single 2025 first-in-human IV safety pilot [10]. TB-500's parent protein, thymosin beta-4, accelerated wound re-epithelialization in rats [1]. KPV reduced colitis severity in mice and inflammatory signaling in human cells [3]. Read it as four parallel research stories, summarized in [the research literature](/research), not as one proven product. ## Why KLOW peptide is not a weight-loss agent None of KLOW's four components is a GLP-1, an incretin, or any established weight-loss agent. KLOW is a tissue-repair-oriented blend — its petals are an anti-inflammatory tripeptide, a matrix-and-copper peptide, an angiogenic peptide and a cytoskeletal peptide. The metabolic framing some sources attach to it is unsupported by the component literature. For the honest evidence picture across all four arms — including the [KLOW peptide benefits](/benefits) people extrapolate and the [reported side effects and safety cautions](/effects) — start with the component studies and the gaps that come with them. Quick answers live in the [frequently asked questions](/faq). --- Four peptides, one bloom of cited research — a plain-English field guide to the studies, never a prescription pad.